Welcome to our dedicated page for Purple Biotech news (Ticker: PPBT), a resource for investors and traders seeking the latest updates and insights on Purple Biotech stock.
Purple Biotech Ltd. (PPBT) generates frequent news as a clinical-stage oncology company developing therapies that, according to its own reports, target tumor immune evasion and drug resistance. Investors and observers following PPBT news can track updates on its CAPTN-3 tri-specific antibody platform, the CEACAM1-blocking antibody CM24, and the dual IRS1/2 and STAT3 inhibitor NT219, as well as financing and listing developments.
Recent press releases highlight CAPTN-3 as a key source of news. The company has announced manufacturing milestones for IM1240, the first tri-specific antibody from the platform targeting 5T4, CD3 and NKG2A, including achievement of a commercially viable yield. Additional updates describe non-human primate toxicology data for IM1240, with Purple Biotech reporting an expanded therapeutic window compared with a non-capped comparator and a pharmacokinetic profile characterized by increased systemic exposure and prolonged half-life in that study.
News flow also covers preclinical data presentations at scientific meetings such as the ESMO Immuno-Oncology Congress and other conferences. These releases describe anti-tumor activity of IM1240 and IM1305 in models resistant to prior PD-1 therapy, transcriptomic analyses supporting the inclusion of an NKG2A arm, and ex vivo results in patient-derived tumor biopsies. Such items provide context on how the company positions CAPTN-3 within immuno-oncology research.
Beyond CAPTN-3, Purple Biotech issues updates on CM24 Phase 2 data in pancreatic ductal adenocarcinoma and on NT219, including an intention to grant a European patent for NT219 combination regimens and progress of a Phase 2 study in recurrent and/or metastatic squamous cell carcinoma of the head and neck. Financial and corporate news includes quarterly results, public offerings of American Depositary Shares and warrants, at-the-market offering agreements, and Nasdaq minimum bid price notifications.
Readers who monitor PPBT news can use this page to follow scientific milestones, regulatory and clinical progress, capital-raising transactions, and listing-related announcements directly sourced from company press releases and SEC-furnished documents.
Purple Biotech (NASDAQ: PPBT) announced a collaboration with Converge Bio on March 25, 2026 to apply proprietary generative AI to accelerate and optimize its next-generation tri-specific antibody platform for oncology. The partnership targets faster discovery, improved developability, and expanded capability against solid-tumor targets.
The collaboration will integrate Converge Bio's AI-driven molecule design with Purple Biotech's CAPTN-3 conditional activation technology to generate optimized T cell engagers and additional high-quality candidates.
Purple Biotech (NASDAQ: PPBT) announced it regained compliance with Nasdaq Listing Rule 5550(a)(2) after its American Depositary Shares maintained a minimum closing bid of $1.00 or more for at least 10 consecutive business days, a condition met on March 13, 2026. The company is now compliant with Nasdaq listing standards.
The company is a clinical-stage immunotherapy developer advancing lead candidates IM1240 and IM1305 and maintaining other clinical-stage assets pending partnering or investment.
Purple Biotech (NASDAQ/TASE: PPBT) announced that Gil Efron will step down as CEO effective August 2026 for health reasons and will transition to lead corporate development while remaining on the Board.
The Board has begun a formal CEO search; the company highlighted continued focus on the CAPTN-3 tri-specific antibody platform and an orderly leadership transition.
Purple Biotech (NASDAQ:PPBT) reported Q4 and full-year 2025 results highlighting advancement of its CAPTN-3 tri-specific antibody program. Lead molecules IM1240 and IM1305 showed positive preclinical efficacy, expanded toxicology window and commercially viable manufacturing yield.
Key figures: cash $9.5M (Dec 31, 2025) with runway into 2027, $20.5M impairment for CM24/NT219, and $26.4M net loss for 2025.
Purple Biotech (NASDAQ: PPBT) will change its American Depositary Share (ADS) ratio from 1 ADS = 200 ordinary shares to 1 ADS = 2,000 ordinary shares, effective at the opening of trading on or about March 2, 2026.
The action is a one-for-ten reverse ADS split aimed at regaining compliance with Nasdaq's $1.00 minimum bid price requirement; ADSs continue to trade under the ticker PPBT and a new CUSIP 74638P307 was assigned.
Purple Biotech (NASDAQ: PPBT) reported that its tri-specific antibody IM1240 from the CAPTN-3 platform completed a non-human primate toxicology study showing an expanded therapeutic window.
Key findings: IM1240 was tolerated at doses up to 300-fold higher than a non-capped comparator (IM1222) with significantly reduced immune-related toxicity and only modest cytokine release. IM1240 also showed a favorable PK profile with increased systemic exposure, dose-proportional AUC and Cmax, and a prolonged circulating half-life attributed to albumin incorporation and capping design. Efficacy in tumor-bearing mice occurred at exposures below those in the Study. The company plans regulatory submission toward first-in-human studies in H2 2026.
Purple Biotech (NASDAQ: PPBT) reported positive preclinical results for its CAPTN-3 tri-specific antibody platform presented at ESMO IO 2025. Two candidates, IM1240 (capped-CD3×5T4×NKG2A) and IM1305 (capped-CD3×TROP2×NKG2A), showed strong anti-tumor activity across multiple solid-tumor models, including activity in PD-1–resistant ex-vivo NSCLC and HNSCC samples. Transcriptomic analysis of ~11,000 TCGA samples supported co-expression of NKG2A with 5T4, justifying the NKG2A arm. IM1305 bound TROP2 and NKG2A (EC50 ~2 nM), showed PBMC-mediated killing at EC50 1–5 pM, and induced sustained tumor regression in humanized TNBC mice (p < 0.0001). Company expects IND-enabling progress and key milestones in 2026.
Purple Biotech (NASDAQ: PPBT) will present new preclinical data from its CAPTN-3 conditionally activated tri-specific antibody platform at ESMO-IO 2025 in London on December 10, 2025. The poster (FPN# 287P) led by Dr. Hadas Reuveni highlights two novel CAPTN-3 platform compounds and preclinical anti-tumor activity, including data in multiple PD-1 resistant models and evidence of engagement of T cells and NK cells against tumor-associated antigens. Management said the findings demonstrate platform versatility and synergy in treatment-resistant cancers. The poster will be posted in the company's Publications section after the congress.
Purple Biotech (NASDAQ: PPBT) reported Q3 2025 results and a business update on Nov 14, 2025. Key financials: $10.5M cash and short-term deposits as of Sept 30, 2025, with an expected cash runway into the first half of 2027. Q3 operating loss was $1.4M and adjusted operating loss $1.3M. R&D expenses declined to $0.6M (56% decrease YoY) largely from reduced CM24 Phase 2 costs.
Clinical and pipeline highlights: IM1240 achieved a commercially viable manufacturing yield and is being advanced toward an IND and Phase 1 initiation in 2026. IM1305 was nominated as a second CAPTN-3 tri-specific candidate targeting TROP2. NT219 Phase 2 and CM24 biomarker-driven plans continue.
Purple Biotech (NASDAQ: PPBT) announced a manufacturing milestone for IM1240, a CAPTN-3 tri-specific antibody targeting 5T4, CD3 and NKG2A. The company reports achieving a commercially viable yield and high-purity process for IM1240, validating CAPTN-3's scalability for complex tri-specific antibodies. IM1240 includes a protease-cleavable, albumin-bound cap intended to limit systemic CD3 activation and extend half-life, concentrating activity in the tumor microenvironment. The program is advancing toward first-in-human studies with an IND submission planned for 2026.